KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $3.8 billion.

  • Teva Pharmaceutical Industries' Other Non-Current Liabilities fell 546.18% to $3.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.8 billion, marking a year-over-year decrease of 546.18%. This contributed to the annual value of $3.8 billion for FY2025, which is 546.18% down from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Other Non-Current Liabilities stood at $3.8 billion, which was down 546.18% from $3.7 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Other Non-Current Liabilities' 5-year high stood at $4.4 billion during Q2 2024, with a 5-year trough of $2.2 billion in Q3 2021.
  • In the last 5 years, Teva Pharmaceutical Industries' Other Non-Current Liabilities had a median value of $3.9 billion in 2022 and averaged $3.6 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Other Non-Current Liabilities surged by 7517.02% in 2022 and then tumbled by 1565.38% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Other Non-Current Liabilities (Quarter) stood at $2.6 billion in 2021, then soared by 53.03% to $3.9 billion in 2022, then increased by 1.88% to $4.0 billion in 2023, then increased by 0.22% to $4.0 billion in 2024, then decreased by 5.46% to $3.8 billion in 2025.
  • Its Other Non-Current Liabilities was $3.8 billion in Q4 2025, compared to $3.7 billion in Q3 2025 and $3.9 billion in Q2 2025.